Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Pfizer Inc. Add to portfolio

NYA:PFE, Aug 17, 03:54 UTC

Latest NYA:PFE News

Filter your feed

Apply Filter

Yesterday


News

3 Terrible Reasons to Sell Pfizer Stock

PFE

The underlying reason is that the drugmaker's shares have dramatically lagged behind the high-flying pharmaceutical industry during the past decade (and for good reason). However, Pfizer's stock has started to show some signs of life this year, gaining a healthy 12% year to date. While some long-suffering shareholders might be tempted to sell following this spike, the usually cited reasons for doubting this big pharma stock appear to be starting to lose credibility. So, with this theme in mind, here is a look at three terrible reasons to sell Pfizer's stock right now. Pfizer seems to be building a firewall against Lyrica's upcoming patent expiration with this product rehousing. Pfizer has been at the epicenter of the politically charged drug pricing debate in the United States, thanks to its regular price hikes on older medicines and its top dog position in the pharmaceutical space. As a result, President Trump specifically targeted Pfizer earlier this year in his criticism of the industry's widespread practice of raising drug prices well above the rate of inflation every year. Read's laser-like focus on the bottom line has arguably come at the expense of the drugmaker's top line. As proof, Wall Street is forecasting Pfizer's revenue to rise at a rather modest 2% compound annual growth rate over the next six years, which is one of the slowest growth rates among large-cap drugmakers. And that's a big reason why Pfizer's stock has been stuck in a rut for the better part of a decade.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

[$$] Pfizer, BioNTech in $425 Million Flu Vaccine Collaboration

PFE

BioNTech said it will receive $120 million in upfront payments from Pfizer, along with up to $305 million in potential milestone payments. The Mainz, Germany, company said it will also receive up to double-digit tiered royalty payments on worldwide sales if the program reaches commercialization. BioNTech and Pfizer will jointly conduct research-and-development activities on mRNA-based flu vaccines, the companies said.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

PFE

BioNTech will receive $120 million in upfront, equity and near-term research payments from Pfizer and will be eligible to receive up to $305 million in potential development, regulatory and commercial milestone payments and up to double-digit royalties. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. mRNA vaccines offer a novel approach to code for any protein or multiple proteins, and the potential to manufacture higher potency flu vaccines more rapidly and at a lower cost than contemporary flu vaccines. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with preliminary data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of any potential product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential indications for Pfizer’s and BioNTech’s potential vaccine candidate for prevention of influenza (flu); whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of Pfizer’s and BioNTech’s potential vaccine candidate for prevention of influenza (flu); and competitive developments.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, August 14


News

Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018

PFE

In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, August 09


News

Examining Pfizer’s Valuation as of August 6

PFE

Pfizer (PFE) is focused on discovering, developing, and manufacturing healthcare products. Pfizer’s portfolio includes medicines, vaccines, and consumer healthcare products. Pfizer’s top line rose ~4% to $13.5 billion in the second quarter of 2018 compared to $12.9 billion in the second quarter of 2017.

Read Full Details

Topics:
  • Business
  • Financial
News

A Look at Recent Developments at Pfizer

PFE

Pfizer’s (PFE) Innovative Health business is focused on developing and commercializing medicines, vaccines, and consumer healthcare products, while its Essential Health business includes legacy brands and generic products, research and development, and its contract manufacturing business.

Read Full Details

Topics:
  • Business
  • Science

Wednesday, August 08


News

These Products Saw Falling Sales in Pfizer’s Q2 2018

PFE

Pfizer’s (PFE) portfolio also includes a few products that are losing market share due to competition from other products in the market. These products include Enbrel (outside the United States and Canada), Sutent, Xalkori, BeneFix, Premarin Family, Medrol, Celebrex, Lyrica, and Viagra.

Read Full Details

Topics:
  • Business
  • Financial
News
News

Examining Pfizer’s Performance by Geography in Q2 2018

PFE

Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. The Innovative Health segment reported a rise of 3% in revenue to ~$4.58 billion, while the Essential Health segment reported a ~14% fall in revenue to $1.65 billion. The rise in the Innovative Health segment was driven by a 5% rise in vaccines sales, a 5% rise in oncology sales, a 33% rise in inflammation and immunology sales, and a 1% rise in consumer healthcare sales.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, August 07


News

Examining Pfizer’s Performance by Segment in Q2 2018

PFE

As we discussed earlier, Pfizer’s (PFE) business is separated into two segments: Innovative Health and Essential Health. The Innovative Health segment contributes over 61.4% of Pfizer’s total revenue. This rise included a 5% rise in operating revenue and a 3% favorable impact of foreign exchange.

Read Full Details

Topics:
  • Business
  • Financial